Drug Design and Delivery Symposium

(DDS #1) Watch this overview of the drug discovery and development process to learn the stages and challenges in every step.

(DDS #2) Listen in on a discussion on the big four druggable families and the difference between small molecule and biotherapeutic targets.

(DDS #3) Discover how drug-likeness is a deceiving concept, explore the Rule of Five, and show how lessons from the past may guide the present.

(DDS #4) Learn strategies on how to effectively optimize small molecule hits and rapidly assess your findings.

(DDS #5) What do you need to know when filing for Investigational New Drug submissions to the United States Food and Drug Administration?

(DDS #6) Learn how the properties of the candidate impact decisions in the discovery process.

(DDS #7) Review the basic principles of Pharmaco-economics in drug development strategies as well as its role in determining health insurance coverage of drug products.

(DDS #8) Explore how how risks and challenges will be dealt with in the future and the key skill sets required of future medicinal chemists.

(January) Learn various factors that can be used to improve candidate quality from Dr. Paul Leeson.

(February) Learn a number of different strategies for improving drug solubility through structural modification.

(March) Finding the right drug target is becoming increasingly difficult. Learn how focusing on the smaller picture can have big results.

(April) Learn the pros and cons of different screening strategies.

(May) Jonathan Baell shares some tips on how to avoid the dead ends of drug discovery.

(June) Join Lei Zhang as he lays out a set of preferred parameters for which has yielded successful PET ligands and reduced resources and timelines.

(July) Jon Mason and Miles Congreve describe what protein-ligand X-ray data can do for you.

(August) Discover the pros and cons of the different solid state forms and what to consider when selecting.

(September) Gain an understanding of acceptable drug delivery approaches to support preclinical dose escalation.

(October) Learn about key concepts including clearance, volume of distribution, half life and protein binding.

(November) John Higgins shares the utility of prodrugs, their general properties and prerequisites for optimal performance.

(January) Robert Copeland starts things off with a look at the importance of target conformational dynamics.

(February) Jules Remenar introduces the basics of LAIs and introduces techniques for using them properly.

(March) Mengwei Hu provides an overview of MR formulation strategies for insoluble compounds.

(April) Our special panel highlight the attributes and capabilities needed by the future medicinal chemist.

(May) Scott Lokey will cover the property space within which drug-like passive membrane permeability can be achieved in traditionally non-druglike scaffolds.

(June) L. Nathan Tumey will provide an overview of how medicinal chemistry strategies can be applied to optimize the efficacy and stability of ADCs.

(July) Punit Seth describes the use of chemical modification strategies to enhance oligonucleotide drugs.

(August) Vincent Stoll of Abbvie and Robert Wenslow of Crystal Pharmatech cover some of the basics of Protein X-ray Crystallography in this special broadcast.

(September) Deepak Dalvie of Pfizer discusses pragmatic risk mitigation strategies for toxicity and the path forward for drug candidates that carry a RM liability.

(October) Matt Disney describe efforts to obtain such compounds to help decipher the varied roles of RNA in disease biology.

(November) Dehua Pei shares how cyclic CPPs may finally realize the potential originally hoped for cell-penetrating peptides

(January) Timothy Heffron will discuss the unmet need for neurooncology treatments and considerations for brain-penentrant kinase inhibitor programs.

(February) Stuart Conway will introduce current understanding of the molecular basis of epigenetic processes, and explain how these findings are being exploited in medicinal chemistry to develop medicines with innovative new mechanisms of action.

(March) Stefan Gross shows how targeting these unique adaptations could lead to drugs with potential to transform clinical outcomes across many cancer types.

(April) Peter Grootenhuis delivers a brief overview of the drug discovery approaches and challenges to identify small molecules CFTR modulators.

(May) Jason Sello describes how applications of conformational analysis, structure-based design, and fragment-based design optimize the medicinal properties of natural products which yield molecules with great potential as drug candidates.

(June) Carl Nathan will review the biology that frames the problem, the innovation gap that exacerbates it and the new work that qualifies TB drug discovery as an innovation engine.

(July) Mike Sofia of Arbutus Biopharma describes viral hepatitis and its impact on human health and the challenges associated with identifying a cure for chronic hepatitis C and hepatitis B virus infections

(August) Kevin Hodgetts of the Harvard Medical School as he discusses the pipeline of therapies for Spinal Muscular Atrophy.

(October) Frank Narjes covers recent advancements in treating this chronic inflammatory disease of the immune system.

Join Dennis Liotta for this special broadcast commemorating of World AIDS Day as he illuminates us on the discovery and development of Emtricitabine which has treated more than ninety percent of all of the HIV-infected persons in the United States.

(November) Laurence Menard and Mary Struthers of BMS discuss the novel approaches to treatment of Lupus from a medicinal chemistry perspective.

Ian Churcher shares how using artificial intelligence technology and other novel approaches in targeted protein degradation could transform drug design.

We've gathered a panel of women to discuss what it takes to create a rewarding and successful career within academia or the pharmaceutical industry as a female.

Marianna Yanez Arteta of AstraZeneca shares how different scattering techniques are being employed to characterize lipid nanoparticles for efficient mRNA delivery.

Vince Rotello shares how nanomaterials provide an ‘outside the box’ alternative that shows considerable promise against these rapidly emerging pathogens.

Join Mansoor Amiji of Northeastern University as he discusses his research over the last 15 years on nanotechnology solutions for enhancing delivery efficiency in solid tumors and overcoming multidrug resistance.

Valentin Gribkoff discusses the degree and nature of the problems of CNS related research and its effects on the willingness of the pharmaceutical industry to invest in the exploration of novel CNS therapies.

Craig Lindsley, of the Vanderbilt Center for Neuroscience Drug Discovery and ACS Chemical Neuroscience shares how to optimize the development of CNS therapeutics as well as achieve high CNS exposure.

Pete Thornton presents data describing a new approach to blocking the receptor signaling pathway which could deliver a novel therapeutic option for chronic pain patients.

Elizabeth de Lange presents the possibility of using mathematical modeling to accurately predict how compounds will affect the brain.

Hadi Valadi discusses how the body can use its own exosomes to naturally transport a cargo of therapeutic RNAs and proteins between cells in order to treat or cure diseases

Mark Murcko of Relay Therapeutics, Ann Weber of Kallyope, John Lowe III of JL3Pharma, and William Greenlee of MedChem Discovery Consulting, give their unique perspectives on what experience and characteristics are vital for medicinal chemists in Pharma.

Heather Carlson discusses the benefits and challenges of this approach as well as how structure-based drug discovery could use these regulatory sites to develop new routes to treating many diseases.

Listen to this panel of successful female computational chemists featuring JCIM Associate Editor Zoe Cournia of the Biomedical Research Foundation Academy of Athens, computational chemistry pioneer Yvonne C. Martin previously of Abbott Laboratories, Principal Scientist Shana Posy of Bristol-Myers Squibb, and Principal Scientist Kate Holloway of Gfree Bio as they share their diverse experiences and backgrounds.

Join Johanna “Hanneke” Jansen as she discusses the concept of “quality” as it pertains to hit-finding and the balance that many drug discovery projects seek between quality and diversity.

Peter Tonge, discusses the factors that affect the translation of sustained occupancy to prolonged drug activity such as target vulnerability and the rate of target turnover which in turn impact the potential benefits of kinetic selectivity.

Join Assistant Professor of Medicine Amit Choudhary from the Broad Institute of Harvard and MIT during this free interactive broadcast as he demonstrates how CRISPR-Cas9 is propelling the discovery and validation of small-molecule-based therapeutics and the development of next-generation therapeutic modalities.

Join Rodney JY Ho as he discusses how the therapeutic use of recombinant T-cells expressing chimeric antigen receptor can provide chemists as well as pharmaceutical and regulatory scientists the opportunity to innovate and define their role in creating precise and personalized medicines.

Join Bart DeCorte of MercachemSyncom to discover the various outsourcing and partnering models and criteria for CRO selection as well as how the partner selection and outsourcing model can be the difference between success and failure.

Fides Benfatti of Syngenta Crop Protection demonstrates through various case studies how much like drug discovery, crop protection research is a daunting challenge that has to be faced with world-class science where both industries can gain valuable insight from each other.

Jesper Lau shares why the discovery of Semaglutide is a fantastic example of how technology and biologic understanding have developed a superior peptide for treatment of diabetes.

Jarkko Rautio of the School of Pharmacy at University of Eastern Finland demonstrates the versatility of prodrugs strategies in medicinal chemistry to overcome various ADMET barriers (absorption, distribution, metabolism, and excretion) with examples of successful prodrugs developed in industry and in academia.

Join Research Fellow Li Di of Pfizer as she discusses why design principles that increase passive permeability are effective approaches to increase oral bioavailability, enhance brain penetration, and reduce renal clearance.

Join Angela Zhou, an Information Scientist at CAS, as she provides an overview of published scientific information relevant to COVID-19 research with an emphasis on patents in the CAS content collection. During this free interactive broadcast, she will highlight antiviral strategies involving small molecules and biologics targeting the complex molecular interactions involved in coronavirus infection and replication.

Join Douglas Kell, Research Chair in Systems Biology at the University of Liverpool, during this free interactive broadcast to discover how drugs pass through cell membrane solely by hitchhiking on membrane transporters and why so-called ‘passive diffusion’ through any bilayer in real cells is negligible.

Jim Thompson discusses some historical case examples of the Moderna mRNA technology platform for the development of prophylactic vaccines and in situ production of neutralizing antibodies for passive immunity and therapeutic applications.

Amanda Garner describes new technologies developed by her group for identifying small molecule inhibitors affecting non-coding RNA biology, as well as new biological discovery platforms for revealing novel druggable pathways in RNA biology.

Bill Wuest discusses how natural product total synthesis is vital for the development of next-generation antibiotics and a fruitful training platform for interdisciplinary science.

Christopher McCurdy of the College of Pharmacy at the University of Florida discusses the possible therapeutic benefits of Kratom as well as the negative consequences of utilizing this tropical tree.

Yvonne Will and Kevin Coe, of Janssen Pharmaceutical discuss the current understanding of the mechanisms that contribute to DILI and how advances in reactive metabolism trapping have improved detection capabilities.

Join Michael Hafey, Wen Kang, and James Monroe as they discuss recent research on various factors that can cause DILI including a bile-salt transport protein and a transcriptomics approach in a micropatterned hepatic coculture system.

Discover how vaccines prepare our immune system to respond to pathogens, explore the scientific, clinical, and production details regarding the vaccine development platforms for the coronavirus, and learn about the global COVID-19 vaccine research landscape and published research.

Dr. Shane Crotty and Dr. Yizhou Dong offer their insights on the progress of COVID-19 vaccine research including the potential for future applications to other diseases and therapeutics.

Brian Lanman of Amgen outlines the strategies used to overcome these challenges of KRAS, one of the most frequently mutated oncogenes in human cancer.

Stephen Buckley of Novo Nordisk shares how this coformulation provides a unique, site-directed release and absorption in the stomach and effectively surmounts inherent challenges relating to solubility, molecular size, and proteolytic lability to achieve therapeutically relevant plasma exposure of semaglutide.